Literature DB >> 22403175

Central role for PELP1 in nonandrogenic activation of the androgen receptor in prostate cancer.

Lin Yang1, Preethi Ravindranathan, Meera Ramanan, Payal Kapur, Stephen R Hammes, Jer-Tsong Hsieh, Ganesh V Raj.   

Abstract

The ability of 17β-estradiol (E2) to regulate the proliferation of prostate cancer (PCa) cells in the absence of androgen is poorly understood. Here, we show the predominant estrogen receptor (ER) isoform expressed in PCa specimens and cell lines is ERβ. Our data indicate that E2 induces the formation of a complex between androgen receptor (AR), ERβ, and a proline-, glutamic acid-, and leucine-rich cofactor protein 1 (PELP1) in PCa cells. This protein complex is formed on AR's cognate DNA-responsive elements on the promoter in response to E2. Formation of this complex enables the transcription of AR-responsive genes in response to E2. Knockdown of PELP1, AR, or ERβ blocks the assembly of this complex, blocks E2-induced genomic activation of AR-regulated genes, and blocks E2-stimulated proliferation of PCa cells. Overall, this study shows that PELP1 may enable E2-induced AR signaling by forming a protein complex between AR, ERβ, and PELP1 on the DNA, leading to the proliferation of PCa cells in the absence of androgen. PELP1 may bridge the signal between E2 bound to ERβ and AR and thus allow for cross talk between these steroid receptors. These data suggest a novel mechanism of AR activation in the absence of androgens in PCa cells. Our data indicate that disruption of the complex between AR and PELP1 may be a viable therapeutic strategy in advanced PCa.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22403175      PMCID: PMC5417135          DOI: 10.1210/me.2011-1101

Source DB:  PubMed          Journal:  Mol Endocrinol        ISSN: 0888-8809


  46 in total

1.  Elevated androgens and prolactin in aromatase-deficient mice cause enlargement, but not malignancy, of the prostate gland.

Authors:  S J McPherson; H Wang; M E Jones; J Pedersen; T P Iismaa; N Wreford; E R Simpson; G P Risbridger
Journal:  Endocrinology       Date:  2001-06       Impact factor: 4.736

Review 2.  Estrogen action on the prostate gland: a critical mix of endocrine and paracrine signaling.

Authors:  Gail P Risbridger; Stuart J Ellem; Stephen J McPherson
Journal:  J Mol Endocrinol       Date:  2007-09       Impact factor: 5.098

3.  Expression of estrogen receptor (ER-alpha and ER-beta) mRNA in human prostate cancer.

Authors:  T Ito; M Tachibana; S Yamamoto; J Nakashima; M Murai
Journal:  Eur Urol       Date:  2001-11       Impact factor: 20.096

4.  Frequent loss of estrogen receptor-beta expression in prostate cancer.

Authors:  L G Horvath; S M Henshall; C S Lee; D R Head; D I Quinn; S Makela; W Delprado; D Golovsky; P C Brenner; G O'Neill; R Kooner; P D Stricker; J J Grygiel; J A Gustafsson; R L Sutherland
Journal:  Cancer Res       Date:  2001-07-15       Impact factor: 12.701

Review 5.  Estrogens and mechanisms of prostate cancer progression.

Authors:  Giuseppe Carruba
Journal:  Ann N Y Acad Sci       Date:  2006-11       Impact factor: 5.691

Review 6.  PELP1: A novel therapeutic target for hormonal cancers.

Authors:  Dimple Chakravarty; Rajeshwar Rao Tekmal; Ratna K Vadlamudi
Journal:  IUBMB Life       Date:  2010-03       Impact factor: 3.885

7.  Mechanisms of androgen receptor activation in advanced prostate cancer: differential co-activator recruitment and gene expression.

Authors:  G N Brooke; M G Parker; C L Bevan
Journal:  Oncogene       Date:  2007-11-26       Impact factor: 9.867

8.  Molecular determinants of resistance to antiandrogen therapy.

Authors:  Charlie D Chen; Derek S Welsbie; Chris Tran; Sung Hee Baek; Randy Chen; Robert Vessella; Michael G Rosenfeld; Charles L Sawyers
Journal:  Nat Med       Date:  2003-12-21       Impact factor: 53.440

9.  Microarray coupled to quantitative RT-PCR analysis of androgen-regulated genes in human LNCaP prostate cancer cells.

Authors:  S Ngan; E A Stronach; A Photiou; J Waxman; S Ali; L Buluwela
Journal:  Oncogene       Date:  2009-04-13       Impact factor: 9.867

10.  The prognostic significance of PELP1 expression in invasive breast cancer with emphasis on the ER-positive luminal-like subtype.

Authors:  Hany Onsy Habashy; Desmond G Powe; Emad A Rakha; Graham Ball; R Douglas Macmillan; Andrew R Green; Ian O Ellis
Journal:  Breast Cancer Res Treat       Date:  2009-06-03       Impact factor: 4.872

View more
  20 in total

1.  PELP1 signaling contributes to medulloblastoma progression by regulating the NF-κB pathway.

Authors:  Yiliao Luo; Mengxing Li; Uday P Pratap; Suryavathi Viswanadhapalli; Junhao Liu; Prabhakar P Venkata; Kristin A Altwegg; Bridgitte E Palacios; Xiaonan Li; Yihong Chen; Manjeet K Rao; Andrew J Brenner; Gangadhara R Sareddy; Ratna K Vadlamudi
Journal:  Mol Carcinog       Date:  2019-12-24       Impact factor: 4.784

Review 2.  Minireview: Deciphering the Cellular Functions of PELP1.

Authors:  Preethi Ravindranathan; Carol A Lange; Ganesh V Raj
Journal:  Mol Endocrinol       Date:  2015-07-09

3.  PELP1 oncogenic functions involve alternative splicing via PRMT6.

Authors:  Monica Mann; Yi Zou; Yidong Chen; Darrell Brann; Ratna Vadlamudi
Journal:  Mol Oncol       Date:  2013-12-30       Impact factor: 6.603

4.  PELP1 overexpression in the mouse mammary gland results in the development of hyperplasia and carcinoma.

Authors:  Valerie Cortez; Cathy Samayoa; Andrea Zamora; Lizatte Martinez; Rajeshwar R Tekmal; Ratna K Vadlamudi
Journal:  Cancer Res       Date:  2014-11-06       Impact factor: 12.701

5.  Peptidomimetic targeting of critical androgen receptor-coregulator interactions in prostate cancer.

Authors:  Preethi Ravindranathan; Tae-Kyung Lee; Lin Yang; Margaret M Centenera; Lisa Butler; Wayne D Tilley; Jer-Tsong Hsieh; Jung-Mo Ahn; Ganesh V Raj
Journal:  Nat Commun       Date:  2013       Impact factor: 14.919

Review 6.  PELP1: Structure, biological function and clinical significance.

Authors:  Gangadhara Reddy Sareddy; Ratna K Vadlamudi
Journal:  Gene       Date:  2016-03-18       Impact factor: 3.688

Review 7.  PELP1: a review of PELP1 interactions, signaling, and biology.

Authors:  Brian J Girard; Andrea R Daniel; Carol A Lange; Julie H Ostrander
Journal:  Mol Cell Endocrinol       Date:  2013-08-08       Impact factor: 4.102

Review 8.  90 YEARS OF PROGESTERONE: Steroid receptors as MAPK signaling sensors in breast cancer: let the fates decide.

Authors:  Amy R Dwyer; Thu H Truong; Julie H Ostrander; Carol A Lange
Journal:  J Mol Endocrinol       Date:  2020-07       Impact factor: 5.098

9.  Targeting GPR30 with G-1: a new therapeutic target for castration-resistant prostate cancer.

Authors:  Hung-Ming Lam; Bin Ouyang; Jing Chen; Jun Ying; Jiang Wang; Chin-Lee Wu; Li Jia; Mario Medvedovic; Robert L Vessella; Shuk-Mei Ho
Journal:  Endocr Relat Cancer       Date:  2014-10-06       Impact factor: 5.678

10.  Reverse yeast two-hybrid system to identify mammalian nuclear receptor residues that interact with ligands and/or antagonists.

Authors:  Hao Li; Wei Dou; Emil Padikkala; Sridhar Mani
Journal:  J Vis Exp       Date:  2013-11-15       Impact factor: 1.355

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.